Ascentage Pharma (亚盛医药) IPO: Updates and Thoughts on HQP1351 (3rd Gen Bcr-Abl TKI)

751 Views19 Jun 2019 13:02
Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key...
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Ke Yan, CFA, FRM
Asia Pac IPO & Placement Research, China biotech
Aequitas Research
EquitiesEquity Capital MarketsQuantitative Analysis
Price Chart(Sign Up to Access)
analytics-chart
x